Gene therapy for relapsed/refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has come back or stopped responding to standard treatments.
- You are able to take care of yourself (fully active or able to do light work).
- You have not been treated with a therapy targeting GPRC5D before.
- You do not have active hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new cell therapy (KSVCBD) for people with multiple myeloma that has returned or not responded to other treatments. It may help if your cancer cells have certain markers, CD19 or BCMA.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new gene therapy for people with multiple myeloma that has come back or hasn't improved with other treatments. It aims to see if the therapy can help control the disease.
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
This early-phase trial tests an investigational cell therapy called LVIVO-TaVec122 for people with certain blood cancers (lymphoma or leukemia) that have come back or not responded to previous treatments. The goal is to see if this new treatment is safe and works for you.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.